Literature DB >> 9151863

Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease.

F Salvatori1, S Masiero, C Giaquinto, C M Wade, A J Brown, L Chieco-Bianchi, A De Rossi.   

Abstract

We addressed the relationship between the origin and evolution of human immunodeficiency virus type 1 (HIV-1) variants and disease outcome in perinatally infected infants by studying the V3 regions of viral variants in samples obtained from five transmitting mothers at delivery and obtained sequentially over the first year of life from their infected infants, two of whom (rapid progressors) rapidly progressed to having AIDS. Phylogenetic analyses disclosed that the V3 sequences from each mother-infant pair clustered together and were clearly distinct from those of the other pairs. Within each pair, the child's sequences formed a monophyletic group, indicating that a single variant initiated the infection in both rapid and slow progressors. Plasma HIV-1 RNA levels increased in all five infants during their first months of life and then declined within the first semester of life only in the three slow progressors. V3 variability increased over time in all infants, but no differences in the pattern of V3 evolution in terms of potential viral phenotype were observed. The numbers of synonymous and nonsynonymous substitutions varied during the first semester of life regardless of viral load, CD4+-cell count, and disease progression. Conversely, during the second semester of life the rate of nonsynonymous substitutions was higher than that of synonymous substitutions in the slow progressors but not in the rapid progressors, thus suggesting a stronger host selective pressure in the former. In view of the proposal that V3 genetic evolution is driven mainly by host immune constraints, these findings suggest that while the immune response to V3 might contribute to regulating viral levels after the first semester of life, it is unlikely to play a determinant role in the initial viral decline soon after birth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151863      PMCID: PMC191691     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

Review 4.  Construction of phylogenetic trees.

Authors:  W M Fitch; E Margoliash
Journal:  Science       Date:  1967-01-20       Impact factor: 47.728

5.  Time course of antigenaemia and seroconversion in infants with vertically acquired HIV-1 infection.

Authors:  A de Rossi; L Ometto; F Mammano; C Zanotto; A del Mistro; C Giaquinto; L Chieco-Bianchi
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  HIV-1-specific cytotoxic T lymphocyte responses in the first year of life.

Authors:  K Luzuriaga; D Holmes; A Hereema; J Wong; D L Panicali; J L Sullivan
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

8.  Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood.

Authors:  J Overbaugh; R J Anderson; J O Ndinya-Achola; J K Kreiss
Journal:  AIDS Res Hum Retroviruses       Date:  1996-01-20       Impact factor: 2.205

9.  Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children.

Authors:  K Luzuriaga; R A Koup; C A Pikora; D B Brettler; J L Sullivan
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

10.  Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers.

Authors:  G Scarlatti; T Leitner; E Halapi; J Wahlberg; P Marchisio; M A Clerici-Schoeller; H Wigzell; E M Fenyö; J Albert; M Uhlén
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

View more
  13 in total

1.  Differential selection of specific human immunodeficiency virus type 1/JC499 variants after mucosal and parenteral inoculation of chimpanzees.

Authors:  Qing Wei; Patricia N Fultz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients.

Authors:  A C Karlsson; H Gaines; M Sällberg; S Lindbäck; A Sönnerborg
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Authors:  V Trouplin; F Salvatori; F Cappello; V Obry; A Brelot; N Heveker; M Alizon; G Scarlatti; F Clavel; F Mammano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice.

Authors:  Elena Priceputu; Zaher Hanna; Chunyan Hu; Marie-Chantal Simard; Patrick Vincent; Steffen Wildum; Michael Schindler; Frank Kirchhoff; Paul Jolicoeur
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

6.  A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.

Authors:  For Yue Tso; Federico G Hoffmann; Damien C Tully; Philippe Lemey; Robert A Rasmussen; Hong Zhang; Ruth M Ruprecht; Charles Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

7.  Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1.

Authors:  C Pasquier; C Cayrou; A Blancher; C Tourne-Petheil; A Berrebi; J Tricoire; J Puel; J Izopet
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.

Authors:  Manish Sagar; Ludo Lavreys; Jared M Baeten; Barbra A Richardson; Kishorchandra Mandaliya; Bhavna H Chohan; Joan K Kreiss; Julie Overbaugh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.

Authors:  Hong Zhang; Federico Hoffmann; Jun He; Xiang He; Chipepo Kankasa; Ruth Ruprecht; John T West; Guillermo Orti; Charles Wood
Journal:  Retrovirology       Date:  2005-11-07       Impact factor: 4.602

10.  The role of genetic variants of Stromal cell-Derived Factor 1 in pediatric HIV-1 infection and disease progression.

Authors:  Ketty Gianesin; Riccardo Freguja; Francesco Carmona; Marisa Zanchetta; Paola Del Bianco; Sandro Malacrida; Marco Montagna; Osvalda Rampon; Carlo Giaquinto; Anita De Rossi
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.